Cargando…
Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
Presuming that Alzheimer’s disease (AD) might represent an antagonistic pleiotropic phenomenon derived from the evolvability of multiple amyloidogenic proteins, targeting such proteins simultaneously could enhance therapeutic efficacy. Furthermore, considering that amyloid-β (Aβ) immunotherapies du...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108623/ https://www.ncbi.nlm.nih.gov/pubmed/35591950 http://dx.doi.org/10.3233/ADR-210021 |
_version_ | 1784708746846404608 |
---|---|
author | Ho, Gilbert Choo, Pei Chen Waragai, Masaaki Inoue, Satoshi Masliah, Eliezer Hashimoto, Makoto |
author_facet | Ho, Gilbert Choo, Pei Chen Waragai, Masaaki Inoue, Satoshi Masliah, Eliezer Hashimoto, Makoto |
author_sort | Ho, Gilbert |
collection | PubMed |
description | Presuming that Alzheimer’s disease (AD) might represent an antagonistic pleiotropic phenomenon derived from the evolvability of multiple amyloidogenic proteins, targeting such proteins simultaneously could enhance therapeutic efficacy. Furthermore, considering that amyloid-β (Aβ) immunotherapies during reproductive life stage might adversely decrease Aβ evolvability in an offspring’s brain, the disease-modifying Aβ immunotherapies should be limited to post-reproductive time in lifespan. Thus, current Aβ immunotherapy strategies should be revised accordingly. Given that the “adiponectin paradox” might underlie both amyloidosis and cognitive dysfunction in aging brain, blocking activin signaling situated downstream of the adiponectin paradox might be an alternative strategy to prevent AD. |
format | Online Article Text |
id | pubmed-9108623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91086232022-05-18 Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability Ho, Gilbert Choo, Pei Chen Waragai, Masaaki Inoue, Satoshi Masliah, Eliezer Hashimoto, Makoto J Alzheimers Dis Rep Commentary Presuming that Alzheimer’s disease (AD) might represent an antagonistic pleiotropic phenomenon derived from the evolvability of multiple amyloidogenic proteins, targeting such proteins simultaneously could enhance therapeutic efficacy. Furthermore, considering that amyloid-β (Aβ) immunotherapies during reproductive life stage might adversely decrease Aβ evolvability in an offspring’s brain, the disease-modifying Aβ immunotherapies should be limited to post-reproductive time in lifespan. Thus, current Aβ immunotherapy strategies should be revised accordingly. Given that the “adiponectin paradox” might underlie both amyloidosis and cognitive dysfunction in aging brain, blocking activin signaling situated downstream of the adiponectin paradox might be an alternative strategy to prevent AD. IOS Press 2022-04-27 /pmc/articles/PMC9108623/ /pubmed/35591950 http://dx.doi.org/10.3233/ADR-210021 Text en © 2022 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Ho, Gilbert Choo, Pei Chen Waragai, Masaaki Inoue, Satoshi Masliah, Eliezer Hashimoto, Makoto Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability |
title | Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability |
title_full | Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability |
title_fullStr | Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability |
title_full_unstemmed | Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability |
title_short | Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability |
title_sort | reconsideration of alzheimer’s disease therapy from a viewpoint of amyloidogenic evolvability |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108623/ https://www.ncbi.nlm.nih.gov/pubmed/35591950 http://dx.doi.org/10.3233/ADR-210021 |
work_keys_str_mv | AT hogilbert reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability AT choopeichen reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability AT waragaimasaaki reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability AT inouesatoshi reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability AT masliaheliezer reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability AT hashimotomakoto reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability |